Common Infusion Reactions with Ocrevus
Ocrevus (ocrelizumab) infusions can trigger reactions in up to 40% of patients during or within 24 hours after administration, mostly mild to moderate. These include itching, rash, flushing, nausea, fatigue, headache, dizziness, fever, sweating, shortness of breath, throat irritation, and pain or burning at the infusion site. Reactions occur more often with the first infusion (about 48%) and decrease with subsequent doses (around 34% for the second, 25% thereafter).[1][2]
How Infusion Reactions Are Managed
Premedication reduces risks: patients typically receive methylprednisolone or another corticosteroid 30 minutes before infusion, plus an antihistamine like diphenhydramine. Infusions start slow (at 50 mg/hour for the first two doses, ramping to 400 mg/hour if tolerated) and last 2.5-3.5 hours initially, shortening to 2 hours after the fourth infusion if no issues arise. Reactions prompt slowing or pausing the infusion; severe cases may require stopping it.[1][3]
Serious Infusion Side Effects and Risks
Rare but serious reactions (less than 1%) include anaphylaxis, cytokine release syndrome, laryngeal edema, bronchospasm, angioedema, or hypotension. Symptoms like severe breathing difficulty, swelling, or chest pain need immediate medical attention. Patients with prior severe reactions to other biologics face higher risk. Long-term, Ocrevus links to increased infection risk, including herpes reactivation or progressive multifocal leukoencephalopathy (PML).[1][2]
Who Experiences Reactions and Prevention Tips
Reactions hit first infusions hardest, especially in MS patients (40-48% rate). No clear predictors like age or prior allergies stand out, but monitoring for 1 hour post-infusion is standard. Home infusions aren't approved due to reaction risks. Report new symptoms to providers; HBV screening is required pre-treatment to avoid reactivation.[1][3]
Ocrevus Infusion vs. Other MS Drugs
Compared to Rituxan (rituximab), Ocrevus has similar but lower reaction rates (34-48% vs. up to 77%) thanks to humanized antibodies and premeds. Alemtuzumab infusions cause more acute reactions (90%), while oral fingolimod avoids them entirely but carries cardiac risks.[2]
[1]: Ocrevus Prescribing Information (Genentech)
[2]: FDA Label for Ocrevus
[3]: National MS Society on Ocrevus